BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37139037)

  • 1. Checkpoint Inhibitor Colitis With Superimposed Clostridioides difficile Infection.
    Mohammad AW; Kusnik A; Mostafa MR; Tan J; Strapko A
    Cureus; 2023 Apr; 15(4):e37006. PubMed ID: 37139037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections.
    Ma W; Gong Z; Abu-Sbeih H; Peng Y; Peng F; Zou F; Charabaty A; Okhuysen PC; McQuade JL; Altan M; Zhang HC; Thomas AS; Wang Y
    Am J Clin Oncol; 2021 Aug; 44(8):402-408. PubMed ID: 34107499
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Vasavada S; Panneerselvam K; Amin R; Varatharajalu K; Okhuysen PC; Oliva ICG; Wang J; Grivas P; Thomas AS; Wang Y
    Ann Gastroenterol; 2022; 35(4):393-399. PubMed ID: 35784625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
    Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection.
    Zhou C; Klionsky Y; Treasure ME; Bruno DS
    Case Rep Oncol; 2019; 12(1):164-170. PubMed ID: 31043955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of refractory immune checkpoint inhibitor-induced colitis with
    Okura Y; Kobayashi K; Yamada Y; Furuya M; Kitano N; Oshina E; Matsuoka M; Nozaka T; Tashiro Y; Sato A; Yauchi M; Matsumoto T; Furumoto Y; Asano T; Azuma S
    DEN Open; 2023 Apr; 3(1):e176. PubMed ID: 36262219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways.
    Sleiman J; Brand RM; Pai R; Brand RE; Rhee J; Schwartz M; Davar D
    Clin J Gastroenterol; 2023 Oct; 16(5):680-684. PubMed ID: 37452993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.
    Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y
    J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.
    Abu-Sbeih H; Ali FS; Naqash AR; Owen DH; Patel S; Otterson GA; Kendra K; Ricciuti B; Chiari R; De Giglio A; Sleiman J; Funchain P; Wills B; Zhang J; Naidoo J; Philpott J; Gao J; Subudhi SK; Wang Y
    J Clin Oncol; 2019 Oct; 37(30):2738-2745. PubMed ID: 31163011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
    Bonanno L; Lorenzi M; Massa D; De Nuzzo M; Angerilli V; Zingone F; Barberio B; Russi A; Girardi F; Ferro A; Dal Maso A; Frega S; Pasello G; Dei Tos AP; Coppola M; Fassan M; Savarino EV; Guarneri V
    Oncologist; 2024 Jan; 29(1):e118-e130. PubMed ID: 37603442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
    Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
    Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event.
    Yamauchi Y; Arai M; Akizue N; Ohta Y; Okimoto K; Matsumura T; Fan MM; Imai C; Tawada A; Kato J; Kato N; Takiguchi Y
    Jpn J Clin Oncol; 2021 Mar; 51(3):363-370. PubMed ID: 33290513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review.
    Gong Z; Wang Y
    JCO Oncol Pract; 2020 Aug; 16(8):453-461. PubMed ID: 32584703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitor-Induced Colitis: How Long Does the Threat Last?
    Calle Sarmiento PM
    Cureus; 2023 Jun; 15(6):e40627. PubMed ID: 37476113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response.
    Zou F; Abu-Sbeih H; Ma W; Peng Y; Qiao W; Wang J; Shah AY; Glitza Oliva IC; Piha-Paul SA; Thompson JA; Zhang HC; Thomas AS; Wang Y
    J Natl Compr Canc Netw; 2020 Dec; 19(6):700-708. PubMed ID: 33316767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer.
    Ofuji K; Hiramatsu K; Nosaka T; Naito T; Takahashi K; Matsuda H; Ohtani M; Imamura Y; Ishizuka T; Nakamoto Y
    Clin J Gastroenterol; 2021 Dec; 14(6):1692-1699. PubMed ID: 34415552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab-Induced Colitis and Diarrhea in the Treatment of Sporadic Colorectal Cancer: A Case Report.
    Jose R; Kaur J; Blanco T; Ehrlich S; Marcelin M
    Cureus; 2024 Jan; 16(1):e52636. PubMed ID: 38374847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexisting cytomegalovirus colitis in an immunocompetent patient with
    Kim JH; Kim HS; Jeong HW
    World J Clin Cases; 2023 Apr; 11(10):2343-2348. PubMed ID: 37122504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab dose escalation triggered immune checkpoint inhibitor-induced colitis after 147 weeks of prolonged stable use in a patient with lung cancer: a case report.
    Soma K; Nishida T; Osugi N; Morimura O; Adachi S; Fujii Y; Sugimoto A; Mukai K; Nakamatsu D; Matsumoto K; Yamamoto M
    Clin J Gastroenterol; 2022 Feb; 15(1):128-133. PubMed ID: 34716545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer.
    Liu C; Shatila M; Mathew A; Machado AP; Thomas A; Zhang HC; Thomas AS; Faleck D; Funchain P; Philpott J; Grivas P; Obeid M; Carbonnel F; Wang Y
    J Cancer; 2023; 14(10):1913-1919. PubMed ID: 37476185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.